New narcolepsy drug aims to keep patients awake and strong

NCT ID NCT07540364

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called samelisant in 240 people with narcolepsy (with or without cataplexy). The goal is to see if it reduces excessive daytime sleepiness and sudden muscle weakness episodes over 12 weeks. Participants will take the drug or a placebo and report their sleepiness levels and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cataplexy Disorders of Excessive Somnolence narcolepsy narcolepsy without cataplexy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••